Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
22.82B
Market cap22.82B
Price-Earnings ratio
16.50
Price-Earnings ratio16.50
Dividend yield
Dividend yield
Average volume
1.93M
Average volume1.93M
High today
$116.02
High today$116.02
Low today
$112.00
Low today$112.00
Open price
$115.97
Open price$115.97
Volume
1.48M
Volume1.48M
52 Week high
$118.97
52 Week high$118.97
52 Week low
$67.17
52 Week low$67.17

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $114.43. The company's market cap stands at 22.82B, with a P/E ratio of 16.50.

During the trading session on 2026-07-13, Incyte(INCY) shares reached a daily high of $116.02 and a low of $112.00. At a current price of $114.43, the stock is +2.2% higher than the low and still -1.4% under the high.

Trading activity shows a volume of 1.48M, compared to an average daily volume of 1.93M.

The stock's 52-week range extends from a low of $67.17 to a high of $118.97.

The stock's 52-week range extends from a low of $67.17 to a high of $118.97.

INCY News

Benzinga 8h
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder

VWD is the most common inherited bleeding disorder, affecting about 1% of the population. It is caused by a deficiency or malfunction of the von Willebrand fac...

Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
TipRanks 9h
Hemab Therapeutics price target raised to $47 from $39 at Jefferies

Jefferies raised the firm’s price target on Hemab Therapeutics (COAG) to $47 from $39 and keeps a Buy rating on the shares after competitor Incyte’s (INCY) Star...

TipRanks 9h
Incyte price target raised to $112 from $94 at BMO Capital

BMO Capital raised the firm’s price target on Incyte (INCY) to $112 from $94 and keeps a Market Perform rating on the shares as part of a broader research note...

Analyst ratings

55%

of 29 ratings
Buy
41.4%
Hold
55.2%
Sell
3.4%

More INCY News

TipRanks 12h
Incyte announces safety, efficacy data from VGA039 study

Incyte (INCY) announced complete safety and efficacy data from all patients enrolled in the Phase 1/2 multidose study of VGA039, a Protein S-targeting, investig...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.